Treatment of severe pulmonary hypertension secondary to scleroderma: A three-drug approach

Internal Medicine

Volumn 47, Issue 6, 2008, Pages 511-513

  Catapano Minotti, Girolamo ^a   Corsonello, Andrea ^b   Guadalupi, Giovanni ^a   Spani, Rosalia ^a   Antonelli Incalzi, Raffaele ^a,c  

^a Fondazione San Raffaele   (Italy)

^b INRCA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Bosentan; Iloprost; Pulmonary hypertension; Scleroderma; Sildenafil

Indexed keywords

BOSENTAN; CALCIUM CARBONATE; COLECALCIFEROL; DOMPERIDONE; ILOPROST; OMEPRAZOLE; OXYGEN; PREDNISONE; SILDENAFIL; VASODILATOR AGENT; WARFARIN; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE; SULFONE;

ADULT; ARTICLE; ASTHENIA; CASE REPORT; DISEASE SEVERITY; DRUG MECHANISM; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; LABORATORY TEST; LUNG HEMODYNAMICS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PULMONARY HYPERTENSION; SCLERODERMA; SYNDROME CREST; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; ELECTROCARDIOGRAPHY; MIDDLE AGED; PATHOPHYSIOLOGY; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MIDDLE AGED; PIPERAZINES; PURINES; SCLERODERMA, SYSTEMIC; SULFONAMIDES; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 41649116752     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0565     Document Type: Article

References (8)

1. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 37: 485-494, 2007.
2. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65: 1336-1340, 2006.
3. McLaughlin VV, Oudiz, RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174: 1257-1263, 2006.
4. Lunze K, Gilbert N, Mebus S, et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 36 (Suppl 3): 32-38, 2006.
5. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 82: 342-350, 2007.
6. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 22: 330-334, 2003.
7. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26: 858-863, 2005.
8. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136: 515-522, 2002.